The apolipoprotein A5 gene (ApoA5) plays an important role in modulating triglyceride metabolism. Polymorphisms of ApoA5, including -1131T>C and c.553G>T (G185C), have been reported to correlate with hypertriglyceridemia (HTG). In the present study the relationships of 5 single nucleotide polymorphisms, including the -1131T>C, c.56C>G, IVS3+476G>A, c.553G>T, and c.1259T>C polymorphisms of ApoA5, with HTG were investigated.
ypertriglyceridemia (HTG) and low plasma levels of high-density lipoprotein (HDL) are common metabolic disorders. HTG is recognized as an independent risk factor for coronary artery disease (CAD); 1 in middle-aged Japanese the fasting triglyceride level is a significant risk factor for CAD. 2 A secondary prevention study of CAD treated with statins suggested that it might be prudent to target fasting triglycerides to less than 150 mg/dl. 3 Apolipoprotein A5 (ApoA5) is a new member of the apolipoprotein gene family, found by a combined approach of comparative sequence analysis 4 and differential gene expression, and it is highly upregulated in the early phase of liver regeneration. 5 Triglyceride levels are 4-fold higher in ApoA5 knockout mice and significantly lower in transgenic mice 4 or adenovirus-treated mice expressing human ApoA5 than in wild-type mice. 6 Several groups have investigated the mechanisms underlying effects of ApoA5 on triglyceride metabolism: it may lower plasma triglyceride levels by increasing lipoprotein lipase activity, 7, 8 or reduce the hepatic level of very-low-density lipoprotein (VLDL) triglycerides. 9 The size and molecular weight of mature human ApoA5 protein are 343 amino acid residues and 39 kDa, respectively. Protein structure analysis predicts that several amphipathic helical domains and an N-terminal signal peptide are characteristic features of apolipoproteins. Human ApoA5 is located approximately 30 kb downstream from the ApoA1/ C3/A4 gene cluster on chromosome 11q23. It contains 4 exons encoding a 1,107-bp open reading frame. Interestingly, 2 initiation codons have been reported, the first was identified by Pennachio et al, 4 and is known to be followed by the second ATG codon, 9 nucleotides downstream, as reported by van der Vliet et al. 5 The National Center for Biotechnology Information reference protein sequence (NP_443200) starts at this second initiation codon. The ApoC3 SstI polymorphism has been associated with altered plasma triglyceride concentrations. 10 Recently, definitive Nterminal protein sequences obtained from ApoA5 purified from human serum were demonstrated. 11 The actual N-terminal sequence of ApoA5 corresponds to that expected from cleavage of the predicted signal peptide, indicating that the mature protein is an intact molecule with a predicted relative molecular mass (Mr) of 39 kDa. Human ApoA5 is fairly polymorphic and 3 common haplotypes have been identified in Caucasians: wild-type haplotype ApoA5*1; ApoA5*2, defined by rare alleles of -1131T>C, -3A>G, IVS3+476G>T, and c.1259T>C; and ApoA5*3, defined by a rare allele of S19W. Therefore, genotyping for -1131T>C or S19W essentially serves to tag single nucleotide polymorphisms (SNPs). 12 The rare C allele of -1131T>C (called SNP3) is more frequent in Japanese (0.34) than in Caucasians (0.08). 13 We previously identified a polymorphism of ApoA5, c.553G>T as ApoA5(G162C), using the amino acid number of mature ApoA5 in Japanese patients with hypertriglyceridemia (abstract; Circulation J 2003 67, Supplement 1: 270). Moreover, Kao et al reported the same polymorphism as ApoA5(G185C) in a Chinese population. 14 This study aimed to evaluate the association of SNPs, including -1131T>C and c.553G>T, of ApoA5 with hypertriglyceridemia in a Japanese population.
Methods

Subjects
The first patient with the ApoA5 polymorphism c.553G> T in our Japanese population was a 62-year-old man who came to the ambulatory clinic of Fukuoka University Hospital because of high plasma levels of triglycerides and glucose. Investigations revealed poorly controlled diabetes mellitus (fasting blood glucose, 187 mg/dl; hemoglobin A1c, 9.4%) and hyperlipidemia (total plasma cholesterol, 529 mg/dl; triglycerides, 2,580 mg/dl; HDL-cholesterol, 18 mg/dl). He also had mild fatty liver on echography, and elevated serum levels of aspartate aminotransferase (39IU/L) and alanine aminotransferase (36 IU/L). No blood samples from his family were available.
For analysis of the frequencies of polymorphisms in subjects with/without HTG, blood specimens of 119 normolipidemic Japanese individuals (80 men, 39 women; age, 58±14 years), and 95 Japanese patients with high levels of fasting plasma triglycerides (76 men, 18 women; age, 56± 12 years) were recruited. Blood was drawn after a 10-h fast. All subjects admitted to the Fukuoka University Hospital were grouped as follows: (1) individuals with HTG: plasma triglyceride level >200 mg/dl; (2) normolipidemic individuals: plasma total cholesterol (TC) level <220 mg/dl and triglyceride <150 mg/dl. The 2 groups did not significantly differ with respect to age and gender. The HTG group had significantly higher TC (p<0.001) and significantly lower HDL-cholesterol (p<0.0001) than the normolipidemic group.
This study was approved by the Ethics Review Committee of Fukuoka University Hospital.
DNA Amplification by Polymerase Chain Reaction (PCR)
Genomic DNA was isolated from 120-l samples of peripheral blood obtained from all subjects. Oligodeoxynucleotide primers used for amplification and sequencing were chosen according to the published ApoA5 structure. Two DNA segments carrying exon 2, exon 3, and exon 4 of ApoA5 of the first patient with the ApoA5 polymorphism c.553G>T were amplified by PCR, using genomic DNA as template. Primer pairs 1 (5'-AAGGAAGGGGTAACAGG-ATTT-3') and 2 (5'-CAACTCACGCACGAAGCACAA-3') for exons 2 and 3; and 3 (5'-TGCTTCGTGCGTGAGTTGT-T-3') and 4 (5'-GACAGCAGCCCCTTTGGTG-3') for exon 4 were used. PCR was performed in reaction volumes of 100 l containing 2.5 U Taq polymerase (Perkin-Elmer Cetus). Amplification was performed by initial denaturation at 96°C for 10 min; followed by 30 cycles at 96°C for 30 s, 60°C for 30 s, and 72°C for 1 min; and a final extension of 7 min at 72°C.
DNA Sequence Analysis
PCR-amplified DNA products were purified with the Geneclean kit (Bio101, La Jolla, CA, USA), and purified DNA fragments were ligated to pT7Blue-T Vector (Novagen, Madison, WI, USA). Following subcloning, double-stranded DNA was sequenced using the BigDye Terminators sequencing kit and the ABI PRISM 373 automated sequencer (PE Biosystems, Branchburg, NJ, USA). Because 2 different translation initiation sites for human ApoA5 have been reported, 5, 12 the G-to-T substitution of exon 3 (c.553G>T) can be shown as ApoA5 (G185C) or (G182C) by 2 different numbers from the translation initiation sites, or as ApoA5 (G162C) using the number from mature ApoA5 amino acid residues. In this study, we used ApoA5 (G185C) from a translation initiation site reported by Pennacchio et al. 12 
Restriction Fragment Length Polymorphism (RFLP) Analysis
Genomic DNA was amplified by PCR using oligonucleotide primers 5 (5'-CTGAAGCCCTACACGATGGA-3') and 6 (5'-GGAAGAGCTCTTTGAAGCGGC-3') for detection of c.553G>T. The PCR product for c.553G>T was digested by restriction enzyme Eco52I. Genotyping for -1131T>C, c.56C>G, IVS+476G>A, and c.1259T>C was carried out by PCR and restriction enzyme digestion, as described previously. 4, 15 Digested fragments were electrophoresed on 8% polyacrylamide gel for 40 min, and DNA fragments were then stained with ethidium bromide.
Haplotype Inference and Linkage Disequilibrium
Haplotypes were inferred on the basis of the diploid sequence data using the PHASE haplotype inference algorithm, version 2.0. 16 Missing genotypes were imputed in the course of the haplotype estimation procedure. Haplotype data for all independent samples were used to calculate pairwise linkage disequilibrium. Inter-locus estimates of linkage disequilibrium were calculated using the software ARLEQUIN, Version 2.00 (http://anthro.unige.ch/arlequin).
Cell Culture Experiment
Human hepatoma (HepG2) cells were maintained in Dulbecco's modified medium (DMEM) supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS, USA) and antibiotics (100 U/ml penicillin, and 100 g/ml streptomycin) at 37°C in a humidified atmosphere of 5% CO2. Cell viability was routinely monitored by trypan blue exclusion. In all experiments, the number of dead cells never exceeded 5% of the total number of cells.
Plasmid Constructs and Transient Expression Assay
The pGL3-ApoA5 (-617/+18)-luc construct was created by inserting a double-stranded oligonucleotide that contained KpnI and NheI restriction sites (Takara Bio, Tokyo, Japan), as described previously. 17 Briefly, amplification of the ApoA5 promoter region was accomplished by PCR with primers JCR45 (5'-AGTCGGTACCTCATGGGGCAAA-TCTTACTTTCGC-3') and JCR95 (5'-AGTCGCTAGCT-CACCTGCTCACGTCTGG-3') (-617 to +18). The 651-bp fragments obtained were subcloned into pT7Blue-T vectors. Genomic subclones were digested with KpnI and NheI, and cloned into pGL3-Basic (Promega). Plasmid phRL-SV40 was also purchased from Promega.
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Generation of Fusion Proteins and Transfection
Expression vectors pSG5-ApoA5 were cloned and prepared from genomic DNA of HepG2 cells. The ApoA5 (G185C) mutant was created using the QuikChange sitedirected mutagenesis kit (Stratagene). In mock transfection control samples, the pEGFP (enhanced green fluorescent protein) vector (Clontech) was used. The ApoA5-GFP and ApoA5(G185C)-GFP expression vectors were constructed by fusing the coding sequence of pEGFP to the 3' end of the ApoA5 coding sequence. HepG2 cells were transfected using the Lipofectin reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The efficiency of transfection in each experiment was estimated by comparison to transfection with pEGFP.
Statistical Analysis
All results are reported as means ± SD, and all p-values were based on 2-sided tests of significance. Differences of mean plasma lipoprotein levels in individuals from different groups were compared using a 1-way analysis of variance. Genotype distributions and deviation from the HardyWeinberg equilibrium were assessed by chi-square analysis.
Results
DNA Sequence Analysis of the ApoA5 Gene
During ApoA5 analysis, we discovered a polymorphism, c.553G>T, in a Japanese patient with HTG (Fig 1A) . Homozygous G-to-T substitution was detected in exon 4 from 12 clones of subcloned DNA fragments, resulting in a single amino acid change of Gly to Cys at amino acid residue 185. The rest of the gene coding sequence was normal. The homozygous c.553G>T polymorphism in the proband was confirmed by RFLP with Eco52I (Fig 1B) . PCR-amplified DNA (190 bp) of ApoA5 obtained from normal subjects was digested with Eco52I, and showed a 168-bp band, indicating an Eco52I site. Digested DNA from the subject with c.553G>T only showed the 190-bp band, which indicated that the subject was homozygous for the defect. Because c.553G>T was detected in other subjects, the variant was defined as a polymorphism.
Frequencies of ApoA5 Polymorphisms
The ApoA5 genomic structure and the locations of the SNPs used to define each haplotype are shown in Fig 2. Frequencies of the 5 polymorphisms, -1131T>C, c.56C>G, IVS3+476G>A, c.553G>T, and c.1259T>C, were determined in 95 Japanese patients with HTG and 119 unrelated normolipidemic subjects. Polymorphisms were determined using restriction patterns of enzymes. Plasma concentrations of lipids and lipoproteins in both groups are shown in Table 1 . Genotype distributions for these polymorphisms were in Hardy-Weinberg equilibrium. As shown in Table 2 , the allelic frequencies of -1131T-to-C and c.1259T-to-C polymorphisms in patients with HTG (0.511 and 0.363) were significantly higher than those of the control subjects (0.315 and 0.210, respectively). Frequency of the T allele of c.553G>T in patients with HTG (0.205) was also significantly higher than that (0.105) of normolipidemic subjects ( Table 2 ). The c.56C>G (S19W) polymorphism was not observed in our Japanese population. No association was observed between the polymorphisms and plasma concentrations of calculated low-density lipoprotein (LDL)-cholesterol, HDL-cholesterol, apoAI, apoAII, apoB or apoE in this study (data not shown). As shown in Table 3 , the other 4 polymorphic sites were in strong linkage disequilibrium. Distributions of the 4 markers vs genotype in the hypertriglyceridemic and normolipidemic subjects are given in Table 4 . There were significant differences between the 2 groups in the overall distribution. Five haplotypes (haplotypes 2, 3, 6, 7, and 8) containing the C allele of -1131T>C were related to HTG among the 8 detected haplotypes.
Functional Studies of Promoter -1131T>C and ApoA5 (G185C)
In order to compare the -1131T>C polymorphism of the human ApoA5 promoter, constructs from -617 to +18 were transiently transfected into HepG2 cells. HepG2 cells were incubated with/without fenofibrate for 24 h. Promoter activities of ApoA5 with/without the -1131T>C polymorphism were estimated by a luciferase assay. We observed that fenofibrate strongly upregulated the activity of both -1131T and -1131C promoters, with over 100% increase when transfected cells were treated with 300 mol/L fenofibric acid (Fig 3) .
We constructed plasmids expressing GFP ApoA5 (ie, ApoA5wt-GFP and ApoA5(G185C)-GFP). To assess the function of these ApoA5-GFP fusion proteins, transfected HepG2 cells were imaged by confocal microscopy. Apo A5wt-GFP was localized to cytoplasmic vesicles, previously shown to be early endosomes, and ApoA5(G185C)-GFP also localized to the cytoplasmic vesicles (Fig 4) . These re- sults suggest that the -1131T>C and c.553G>T (G185C) polymorphisms do not exert a direct influence on ApoA5 expression.
Discussion
We have shown that (1) the -1131T>C, c.1259T>C and c.553G>T polymorphisms are positively associated with HTG in Japanese; (2) the -1131T>C, IVS3+476G>A, c.553G>T, and c.1259T>C polymorphisms are in linkage disequilibrium; and (3) the -1131T>C polymorphism is a stronger determinant of HTG than c.553G>T. Additional in vitro studies showed that the promoter activities of ApoA5 with/without the -1131T>C polymorphism do not differ, and that ApoA5wt-GFP and ApoA5(G185C)-GFP similarly localize to cytoplasmic vesicles in HepG2 cells.
The ApoA5 SNPs have been associated with HTG, 12,13 reduced HDL-cholesterol (-1131T>C, -3A>G and IVS3+ 476A>G), 18 decreased LDL-cholesterol size (-3A>G and c.1259T>C), 19 and increased numbers of remnant-like particles (-1131T>C and c.56C>G). 20 No significant differences have been observed in fasting and postprandial concentrations of serum glucose, insulin, and free fatty acids among subjects with the -1131T>C polymorphism. 21 The -1131T >C SNP was more frequent in CAD patients. 22 Both the -1131T>C and c.56C>G SNPs have been associated with cardiovascular events, 20 but not with coronary artery diameter. 23 The rare allele of -1131T>C has also been associated with stroke. 24 Several SNPs in human ApoA5 have been detected, with differing frequencies depending on the population analyzed. Common SNPs, including -1131T>C, -3A>G, c.56C>G, IVS3+476G>A, and c.1259T>C, have been widely reported. 20, 12 Pennacchio et al showed that there were 3 major haplotypes (ie, ApoA5*1, *2, and *3) that accounted for 97.6% of haplotypes in a Caucasian population, containing the SNPs -1131T>C, c.-3A>G, c.56C>G, IVS3+476G>A, and c.1259T>C. 12 ApoA5*1 is defined as all the major alleles being present. Because of strong linkage disequilibrium between these SNPs, haplotype ApoA5*2 can be defined as the occurrence of the minor allele at -1131T>C, c.-3A>G, IVS3+476A, or c.1259T>C, whereas ApoA5*3 is defined as the c.56G allele. Therefore, 2 independent ApoA5 SNPs (c.56C>G and -1131T>C) can be analyzed in association studies as indicators of the corresponding haplotypes. However, compared with Caucasians, in Turks, Singaporeans, and African-Americans the ApoA5 haplotype structure is more complex. 18, 25 The -1131T>C poly- morphism is in strong, but incomplete, linkage disequilibrium with the 3 other SNPs in Turks and Singaporeans, 18 and the c.1259T>C polymorphism is very rare in AfricanAmericans (0.001%). 25 Our results indicate that -1131T>C, IVS3+476G>A, c.553G>T, and c.1259T>C polymorphisms in Japanese are in linkage disequilibrium, and that c.56C>G is absent or very rare. The c.553G>T polymorphism, with an allelic frequency of 4.2%, was significantly associated with increased triglyceride levels in a Chinese population, 14 but was very rare in a Turkish population (0.6% allelic frequency), and extremely rare or absent in Caucasians. 12, 26 Nabika et al reported that the calculated frequency of the -1131C allele was 0.34. 27 In the present study, we showed that the -1131T>C and c.553T>C polymorphisms of ApoA5 were in strong linkage disequilibrium, and the allelic frequencies of -1131T>C (0.315) and c.553G>T (0.105) in the normolipidemic Japanese subjects were relatively high. The c.56C>G polymorphism consists of a non-synonymous substitution, changing codon 19 from serine to tryptophan (S19W); however, we could not find the c.56C>G polymorphism in this Japanese population. Univariate analyses showed that the allelic frequencies of -1131T>C (0.511) and c.553G>T (0.205) in subjects with HTG were significantly higher than in normolipidemic subjects. Because ApoA5 polymorphisms have been associated with high plasma levels of triglyceride, SNP-associated increases may reflect impaired function of ApoA5. The -1131T>C polymorphism is located in the promoter region, and may alter ApoA5 expression. However, in our luciferase reporter gene assay, both the -1131T and -1131C promoter constructs with fenofibric acid showed a significant increase in luciferase expression level (Fig 3) . Prieur et al 17 and Talmud et al 28 also concluded on a lack of functionality of -1131T>C. Therefore, we conclude that a -1131T>C change within the promoter does not affect promoter activity. Talmud et al 15 demonstrated that the -1131T>C polymorphism of ApoA5 was within a linkage disequilibrium block of approximately 50 kb (up to-482C>T of the ApoC3 gene), which was strongly associated with plasma triglyceride level. The triglyceride-raising effect of -1131T>C might reflect the linkage disequilibrium between ApoA5 -1131C and the triglyceride-raising ApoC3 -482T allele. Because ApoA5 displays high affinity, low elasticity, and slow binding kinetics at hydrophobic interfaces, 29 it has been postulated that it might retard triglyceride-rich particle assembly in the liver and inhibit secretion of VLDL. Secretion of ApoA5 by COS1 cells transfected with ApoA5 complementary DNA was found to be greatly reduced, compared with other human plasma proteins, as a result of retention of ApoA5 in the endoplasmic reticulum. 29 Adenovirus-mediated hepatic ApoA5 expression in mice decreased the VLDL-triglyceride production rate in a dose-dependent manner, without an effect on VLDL particle numbers, suggesting that ApoA5 affected lipidation of apolipoprotein B during VLDL assembly. 9 Results from ApoA5(Q148X) carriers and the adenovirus-mediated gene transfer of ApoA5 into wild-type mice showed that lipoprotein lipase activation by ApoA5 might play an important role in its function and in repression of the VLDL production rate. 6 The G185C substitution within human ApoA5 is adjacent to a typical proline-directed amphipathic -helix (residues 190-211). The G185C variation might form an intramolecular disulfide bond with Cys227 of human ApoA5, which is highly conserved, resulting in a conformational change in the tertiary structure of the ApoA5 variant. However, in the present study GFP-positive particles, endosomes, were discernible in both wild-type ApoA5 and ApoA5(G185C)-transfected HepG2 cells (Fig 4) . These results suggest that ApoA5(G185C) and the wild type were, at least, similarly expressed and assembled in the endosomes of HepG2 cells. The biological consequence of the G185C polymorphism deserves further investigation. Although in vitro studies have their limitations, the -1131T>C polymorphism did not affect promoter activity, as estimated by the luciferase assay, and ApoA5wt -GFP and ApoA5(G185C)-GFP were similarly expressed in the endosomes.
In conclusion, ApoA5 -1131T>C and c.553G>T polymorphisms were associated with triglyceride level in Japanese. The strong linkage disequilibrium between the -1131T>C and c.553G>T polymorphisms was identified in our haplotype analysis. Promoter activities of ApoA5 with the common or mutated allele were not different in HepG2 cells. Further studies are needed to establish the mechanisms of action associated with the presence of these allelic variations.
